knowledge -WSS

knowledge

author：focus 2025-10-04 04:00:06 - browse：3196

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — This week, European regulators are considering an appeal from Amylyx Pharmaceuticals after initially recommending against approving the company’s ALS treatment — the latest potential turning point for a drug that has seen its share of ups and downs with regulatory bodies.

In June, a European Medicines Agency committee issued a negative review of Amylyx’s drug, called Albrioza, and cast doubt on whether it had demonstrated effectiveness in its pivotal study. That would have almost certainly led to a rejection by regulators, but Amylyx requested what’s called a re-examination of the opinion. On Tuesday, the EMA held a meeting on the appeal, and a decision is expected in the coming weeks.

“There are patients who are dying and they really want access to the drug,” said Evy Reviers, the chairwoman of the European Organization for Professionals and Patients with ALS, whose father has the neurological disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Venture capitalist Bob Kocher on the state of digital health

WSS

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

FDA greenlights medical device to combat bladder issues

Helping hospitals and community health centers plan for resilience

National associations that represent hospice owe an apology

Addiction experts warn against a second 'war on drugs'

When prostate cancer spreads, where it goes matters

focus

knowledge

focus

At least 13 dead in Texas as scorching temps continue

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Supreme Court strikes down use of affirmative action

Case highlights the risks of experimental stem cell therapy

Dobbs anniversary: the lost opportunity of abortion as health care

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Dobbs anniversary: the lost opportunity of abortion as health care

Military medical care influenced by rank and race, new study finds

At least 13 dead in Texas as scorching temps continue

Wegovy improves function in certain heart failure patients

hotspot

Cytokinetics CEO stresses company can launch heart drug on its own

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Bird flu: Don't repeat Covid's 'health versus the economy' framing

CDC says it’s too soon to assess risk posed by Covid subvariant

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Hospital at home shows how to bring innovation to health care

focus

leisure time

knowledge

hotspot